Vc-MMADPotent tubulin inhibitor CAS# 1401963-17-4 |
- Mc-MMAD
Catalog No.:BCC1735
CAS No.:1401963-15-2
- Docetaxel Trihydrate
Catalog No.:BCC1535
CAS No.:148408-66-6
- Colchicine
Catalog No.:BCN6271
CAS No.:64-86-8
- D-64131
Catalog No.:BCC1510
CAS No.:74588-78-6
- 7-Xylosyltaxol
Catalog No.:BCN5341
CAS No.:90332-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1401963-17-4 | SDF | Download SDF |
PubChem ID | 78357803 | Appearance | Powder |
Formula | C70H104N12O14S | M.Wt | 1369.71 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate | ||
SMILES | CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC4=CC=C(C=C4)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN5C(=O)C=CC5=O | ||
Standard InChIKey | GRBICHHPFYWKKI-BDVWXETGSA-N | ||
Standard InChI | InChI=1S/C70H104N12O14S/c1-14-45(8)61(53(94-12)40-57(86)81-37-22-26-52(81)62(95-13)46(9)63(87)76-51(67-72-35-38-97-67)39-47-23-17-15-18-24-47)79(10)68(91)59(43(4)5)78-66(90)60(44(6)7)80(11)70(93)96-41-48-28-30-49(31-29-48)74-64(88)50(25-21-34-73-69(71)92)75-65(89)58(42(2)3)77-54(83)27-19-16-20-36-82-55(84)32-33-56(82)85/h15,17-18,23-24,28-33,35,38,42-46,50-53,58-62H,14,16,19-22,25-27,34,36-37,39-41H2,1-13H3,(H,74,88)(H,75,89)(H,76,87)(H,77,83)(H,78,90)(H3,71,73,92)/t45-,46+,50-,51-,52-,53+,58-,59-,60-,61-,62+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate.
IC50 Valu: N/A
Target: tubulin; ADCs
Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate.
For comparison purposes, the ADC A1 -mc-MMAD and/or A1 -vc-MMAD were used. The linker payload, mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D) was conjugated to the A1 anti-5T4 monoclonal antibody through a cysteine residue at a ratio of approximately 4 drug moieties per antibody molecule. The linker payload mc- Val-Cit-PABA-MMAD or vc-MMAD (maleimidocapronic -valine-citruline-p- aminobenzyloxycarbonyl- monomethylauristatin-D) was conjugated to the A1 anti-5T4 monoclonal antibody through a cysteine residue at a ratio of approximately 4 drug moieties per antibody molecule (Antibody-drug conjugates Patent: WO 2013068874 A1). References: |
Vc-MMAD Dilution Calculator
Vc-MMAD Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 0.7301 mL | 3.6504 mL | 7.3008 mL | 14.6016 mL | 18.252 mL |
5 mM | 0.146 mL | 0.7301 mL | 1.4602 mL | 2.9203 mL | 3.6504 mL |
10 mM | 0.073 mL | 0.365 mL | 0.7301 mL | 1.4602 mL | 1.8252 mL |
50 mM | 0.0146 mL | 0.073 mL | 0.146 mL | 0.292 mL | 0.365 mL |
100 mM | 0.0073 mL | 0.0365 mL | 0.073 mL | 0.146 mL | 0.1825 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload and antibody drug conjugate. For comparison purposes, the ADC A1 -mc-MMAD and/or A1 -vc-MMAD were used. The linker payload, mc-MMAD (6-maleimidocaproyl-monomethylauristatin-D) was conjugated to the A1 anti-5T4 monoclonal antibody through a cysteine residue at a ratio of approximately 4 drug moieties per antibody molecule. The linker payload mc- Val-Cit-PABA-MMAD or vc-MMAD (maleimidocapronic -valine-citruline-p- aminobenzyloxycarbonyl- monomethylauristatin-D) was conjugated to the A1 anti-5T4 monoclonal antibody through a cysteine residue at a ratio of approximately 4 drug moieties per antibody molecule (Antibody-drug conjugates Patent: WO 2013068874 A1).
- Mc-MMAD
Catalog No.:BCC1735
CAS No.:1401963-15-2
- (S)-(-)-5-Iodowillardiine
Catalog No.:BCC6597
CAS No.:140187-25-3
- (S)-(-)-5-Fluorowillardiine
Catalog No.:BCC6596
CAS No.:140187-23-1
- Monnieriside A
Catalog No.:BCN7892
CAS No.:1401807-73-5
- Monnieriside G
Catalog No.:BCN7857
CAS No.:1401799-34-5
- (-)-Praeruptorin A
Catalog No.:BCN7664
CAS No.:14017-71-1
- Negundonorin A
Catalog No.:BCN7150
CAS No.:1401618-51-6
- ATPA
Catalog No.:BCC6940
CAS No.:140158-50-5
- Epimedin A1
Catalog No.:BCN5935
CAS No.:140147-77-9
- Pterisolic acid F
Catalog No.:BCN4840
CAS No.:1401419-90-6
- Pterisolic acid E
Catalog No.:BCN4841
CAS No.:1401419-89-3
- Pterisolic acid D
Catalog No.:BCN4839
CAS No.:1401419-88-2
- GSK2879552
Catalog No.:BCC6422
CAS No.:1401966-69-5
- Psiguadial D
Catalog No.:BCN7086
CAS No.:1402066-95-8
- Eupalinolide I
Catalog No.:BCN7367
CAS No.:1402067-84-8
- TUG-770
Catalog No.:BCC2018
CAS No.:1402601-82-4
- Boc-Lys(2-Cl-Z)-ol
Catalog No.:BCC2581
CAS No.:14028-05-8
- Amoxapine
Catalog No.:BCC4624
CAS No.:14028-44-5
- N-Methyllindcarpine
Catalog No.:BCN6218
CAS No.:14028-97-8
- NLG919
Catalog No.:BCC2325
CAS No.:1402836-58-1
- Chetomin
Catalog No.:BCC2432
CAS No.:1403-36-7
- Squalene-2,3-diol
Catalog No.:BCN6220
CAS No.:14031-37-9
- EPZ-6438
Catalog No.:BCC3634
CAS No.:1403254-99-8
- Macranthoidin A
Catalog No.:BCN2808
CAS No.:140360-29-8